156.39
0.08%
-0.12
アフターアワーズ:
156.39
前日終値:
$156.51
開ける:
$157.24
24時間の取引高:
520.94K
Relative Volume:
0.92
時価総額:
$8.59B
収益:
$360.35M
当期純損益:
$-149.57M
株価収益率:
-52.83
EPS:
-2.96
ネットキャッシュフロー:
$-81.27M
1週間 パフォーマンス:
-0.09%
1か月 パフォーマンス:
+6.86%
6か月 パフォーマンス:
+25.96%
1年 パフォーマンス:
+74.99%
Glaukos Corporation Stock (GKOS) Company Profile
GKOS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
156.39 | 8.59B | 360.35M | -149.57M | -81.27M | -2.96 |
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
2024-12-06 | 開始されました | UBS | Buy |
2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
2024-05-06 | アップグレード | Jefferies | Hold → Buy |
2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
2023-11-28 | 開始されました | Truist | Buy |
2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-12-22 | 開始されました | Mizuho | Neutral |
2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
2022-10-14 | 再開されました | Stephens | Overweight |
2022-10-04 | 開始されました | Needham | Buy |
2022-07-12 | アップグレード | Stifel | Hold → Buy |
2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
2020-12-09 | 開始されました | Oppenheimer | Perform |
2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2020-06-15 | 開始されました | Jefferies | Hold |
2020-03-05 | 開始されました | Citigroup | Sell |
2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-01-06 | アップグレード | Berenberg | Hold → Buy |
2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
2019-03-08 | 開始されました | BTIG Research | Neutral |
2018-08-30 | 開始されました | Berenberg | Hold |
2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
2018-08-03 | 繰り返されました | Stifel | Hold |
2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-04-13 | ダウングレード | Stifel | Buy → Hold |
2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
2017-01-06 | アップグレード | Stifel | Hold → Buy |
2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corporation (GKOS) 最新ニュース
Assenagon Asset Management S.A. Decreases Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Personal Finance - Business Wire
Glaukos Shares Rise Amid Promising Trial Results - TipRanks
GKOS Stock Gains Following Positive Study Data on iDose Platform - MSN
(GKOS) Trading Signals - Stock Traders Daily
Glaukos reports sustained efficacy in iDose TR trials By Investing.com - Investing.com South Africa
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
Glaukos reports sustained efficacy in iDose TR trials - Investing.com
Glaukos Highlights Advances in Glaucoma Treatments - TipRanks
Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3 - TipRanks
Glaukos iDose TR Shows Strong 36-Month Results with 70% Patient Control Rate in Glaucoma Trial - StockTitan
Thomas Burns: The 2-Decade Bet That’s Paying Off - Orange County Business Journal
Here's Why You Should Add Glaukos Stock to Your Portfolio Now - MSN
Harbor Capital Advisors Inc. Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? - MSN
Glaukos stock soars to all-time high of $153.72 By Investing.com - Investing.com Nigeria
Glaukos (NYSE:GKOS) Hits New 1-Year HighStill a Buy? - MarketBeat
Glaukos stock soars to all-time high of $153.72 - Investing.com
(GKOS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Glaukos price target raised to $157 from $149 at BTIG - Yahoo Finance
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Benzinga
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Stifel backs Glaukos shares with higher price target and positive long-term iDose outlook - Investing.com Canada
Glaukos Corporation Sees A Bright Future In Huntsville - Huntsville Business Journal
Franklin Resources Inc. Purchases 6,948 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA - MSN
GKOS (Glaukos) Change In Working Capital : $-36.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
(GKOS)Analyzing Glaukos's Short Interest - Benzinga
(GKOS) Trading Report - Stock Traders Daily
Are Investors Undervaluing Glaukos Corporation (NYSE:GKOS) By 50%? - Simply Wall St
Glaukos (NYSE:GKOS) Reaches New 1-Year HighTime to Buy? - MarketBeat
Pharmaceutical giant chooses to invest $82 million in Huntsville facility - MSN
Glaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos president sells $498,715 in stock - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million By Investing.com - Investing.com Australia
Glaukos president sells $498,715 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Glaukos Corporation (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):